Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

237 Views

Poster Session: HIV: Treatment

1267 - Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results from the TANGO and SALSA Studies

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Co-Author(s)

MP

Manyu Prakash, PhD

ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom
RG

Richard Grove, MSc

Manager, Statistics
GlaxoSmithKline, Brentford, UK
Brentford, England, United Kingdom
BW

Brian R. Wynne, M.D.

Medicine Development Lead for Dolutegravir
ViiV Healthcare, Research Triangle Park, NC, USA
Chagrin Falls, Ohio, United States
CM

Choy Man, BSc

Clinical Development Director
ViiV Healthcare, Research Triangle Park, NC, USA
Research Triangle Park, North Carolina, United States
Jv

Jean A. van Wyk, MBChB, MFPM

Medical Director
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom
CJ

Clifford B. Jones, BSc MSc MB ChB

Global medical lead
ViiV Healthcare, Brentford, UK
London, England, United Kingdom
CO

Chinyere Okoli, MSc, DIP

Global Scientific Advisor
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom

Presenting Author(s)

Emilio Letang, MD, MPH, PhD

Global Scientific Advisor
ViiV Healthcare, Madrid, Spain
Madrid, Madrid, Spain

Co-Author(s)

Mounir Ait-Khaled, PhD

Clinical Science Director
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom
AC

Andrew Clark, MD

Global Medical Lead
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom